Stay updated on Durvalumab and Tremelimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.

Latest updates to the Durvalumab and Tremelimumab in NSCLC Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the Record History page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedAdded a site-wide revision note (Revision: v3.3.3) and removed the HHS Vulnerability Disclosure link along with Revision: v3.3.2; these are UI/policy updates and do not alter the clinical trial record data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page footer now shows Revision: v3.3.2, replacing Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision: v3.3.1 was added and revision: v3.2.0 was removed.SummaryDifference0.1%

- Check59 days agoChange DetectedThe government funding/status notice banner was removed from the page, and it does not affect the trial record or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check74 days agoChange DetectedDifference0.1%

Stay in the know with updates to Durvalumab and Tremelimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.